In a phase 1b study, a PD-1 inhibitor, nivolumab, was administered to patients with relapsed or refractory hematologic malignancies, including twenty-seven patients with multiple myeloma [95]. The gene discussed is PDCD1; the disease is plasma cell myeloma.